NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

MoonLake Immunotherapeutics logo
$11.25 -0.48 (-4.09%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$11.46 +0.21 (+1.88%)
As of 11/17/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

Advanced

Key Stats

Today's Range
$10.93
▼
$11.80
50-Day Range
$9.55
▼
$13.72
52-Week Range
$9.46
▼
$23.29
Volume
1.18 million shs
Average Volume
1.67 million shs
Market Capitalization
$957.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.33
Consensus Rating
Moderate Buy

Company Overview

MoonLake Immunotherapeutics is a Switzerland-based clinical-stage biopharmaceutical company focused on developing treatments for inflammatory skin and joint diseases. The company was established in 2021 and is headquartered in Zug.

Its lead investigational medicine, sonelokimab, is a nanobody designed to inhibit the inflammatory proteins IL-17A and IL-17F. MoonLake is studying the drug as a potential treatment for conditions including hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis.

Sonelokimab has not been approved for commercial use. MoonLake’s work centers on clinical development of this candidate and evaluating its potential across multiple inflammatory diseases.

AI Generated. May Contain Errors.

MoonLake Immunotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

MLTX MarketRank™: 
3.402 of 5 stars

MoonLake Immunotherapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 230th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MoonLake Immunotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and 2 sell ratings.

  • Upside Potential

    MoonLake Immunotherapeutics has a consensus price target of $31.33, representing about 178.5% upside from its current price of $11.25.

  • Amount of Analyst Coverage

    MoonLake Immunotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about MoonLake Immunotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for MoonLake Immunotherapeutics are expected to grow in the coming year, from ($3.57) to ($3.53) per share.

  • Price to Book Value per Share Ratio

    MoonLake Immunotherapeutics has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.18% of the float of MoonLake Immunotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 2.85, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MoonLake Immunotherapeutics has recently decreased by 30.13%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    MoonLake Immunotherapeutics does not currently pay a dividend.

  • Dividend Growth

    MoonLake Immunotherapeutics does not have a long track record of dividend growth.

  • News Sentiment

    MoonLake Immunotherapeutics has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for MoonLake Immunotherapeutics this week, compared to 7 articles on an average week.
  • MarketBeat Follows

    2 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MoonLake Immunotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.40% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MoonLake Immunotherapeutics' insider trading history.
Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MLTX Stock News Headlines

What is HC Wainwright's Estimate for MLTX FY2026 Earnings?
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
MoonLake Immunotherapeutics (MLTX) Gets a Buy from Guggenheim
See More Headlines

MLTX Stock Analysis - Frequently Asked Questions

MoonLake Immunotherapeutics' stock was trading at $13.18 on January 1st, 2026. Since then, MLTX shares have decreased by 14.6% and is now trading at $11.25.

MoonLake Immunotherapeutics (NASDAQ:MLTX) issued its quarterly earnings results on Wednesday, November, 4th. The company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by $0.10.

MoonLake Immunotherapeutics (MLTX) raised $100 million in an initial public offering (IPO) on Tuesday, October 20th 2020. The company issued 10,000,000 shares at a price of $10.00 per share.

Top institutional investors of MoonLake Immunotherapeutics include Goldman Sachs Group Inc. (0.83%), Jump Financial LLC (0.69%), Candriam S.C.A. (0.64%) and Congress Asset Management Co. (0.26%). Insiders that own company stock include Da Silva Jorge Santos, Kristian Reich, Bvf Partners L P/Il, Matthias Bodenstedt and Simon Sturge.
View institutional ownership trends
.

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MoonLake Immunotherapeutics investors own include Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Intel (INTC), Micron Technology (MU), Quantum Computing (QUBT), Rocket Lab (RKLB) and Super Micro Computer (SMCI).

Company Calendar

Last Earnings
11/04/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MLTX
CIK
1821586
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

High Price Target
$57.00
Low Price Target
$10.00
Potential Upside/Downside
+178.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$227.32 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-79.95%
Return on Assets
-56.40%

Debt

Debt-to-Equity Ratio
0.26
Current Ratio
9.13
Quick Ratio
9.13

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.48 per share
Price / Book
2.51

Miscellaneous

Outstanding Shares
85,110,000
Free Float
76,256,000
Market Cap
$957.49 million
Optionable
Optionable
Beta
1.14
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:MLTX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners